Tofranil Withdrawal & Tapering Guide
imipramine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial antidepressant treatment.
In short
Tofranil (imipramine) is a TCA with a half-life of 11-25 hours (parent); active metabolite desipramine 12-24 hours. Slow hyperbolic taper recommended due to anticholinergic rebound. Withdrawal symptoms, when they occur, usually begin 1-3 days after dose reduction and settle within 2-6 weeks for most symptoms. It is also sold as Janimine.
- Class
- TCA
- Half-life
- 11-25 hours (parent); active metabolite desipramine 12-24 hours
- Common doses
- 10mg, 25mg, 50mg tablets; 75mg, 100mg, 125mg, 150mg capsules
- Withdrawal onset
- 1-3 days after dose reduction
- Typical resolution
- 2-6 weeks for most symptoms
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Imipramine is the prototype tricyclic antidepressant, FDA-approved for major depression and pediatric enuresis (bedwetting). Largely displaced by SSRIs but still used for treatment-resistant depression, panic disorder, and chronic pain.
10mg, 25mg, 50mg tablets; 75mg, 100mg, 125mg, 150mg capsules
Tablets: 10mg, 25mg, 50mg; Capsules (pamoate): 75mg, 100mg, 125mg, 150mg
Category C
Mechanism of Action
Inhibits reuptake of both serotonin and norepinephrine at the presynaptic terminal. Also blocks histamine H1, muscarinic, and alpha-1 adrenergic receptors — these "off-target" actions explain most of the side-effect profile.
Taper Notes
Slow hyperbolic taper recommended due to anticholinergic rebound. Compounded liquid useful for fine cuts at the low end.
Hyperbolic Tapering Guidance
Reduce by smaller proportional steps as the dose gets lower. Cholinergic rebound (sweating, abdominal cramps, malaise) is common and often misread as relapse.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days after dose reduction
5-10 days
2-6 weeks for most symptoms
Sleep disturbance and emotional reactivity can persist 1-3 months
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome, hypertensive crisis)
- CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) — markedly increase imipramine levels
- QT-prolonging agents — additive arrhythmia risk
Contraindications
- Recent (within 14 days) MAOI use
- Acute recovery phase after myocardial infarction
- Narrow-angle glaucoma (relative)
Toxicity
Highly toxic in overdose — narrow therapeutic index. Cardiac arrhythmias, seizures, anticholinergic toxicity, coma. Even 1-2 weeks of supply can be lethal.
Pharmacokinetics
ADME Profile
Well absorbed orally; extensive first-pass metabolism.
Hepatic via CYP1A2, CYP2C19, CYP2D6, CYP3A4 to active desipramine.
Renal (80%) and fecal (20%) as metabolites.
~90%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing TCA medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 75 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (75 mg start) |
|---|---|---|
| Start | 100% | 75 mg |
| Step 1 | 90% | 67.5 mg |
| Step 2 | 81% | 60.8 mg |
| Step 3 | 73% | 54.7 mg |
| Step 4 | 66% | 49.2 mg |
| Step 5 | 59% | 44.3 mg |
| Step 6 | 53% | 39.9 mg |
| Step 7 | 48% | 35.9 mg |
| Step 8 | 43% | 32.3 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Tofranil, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Tofranil
What are the withdrawal symptoms of Tofranil (imipramine)?
Common withdrawal symptoms of Tofranil (imipramine) include: flu-like symptoms, GI upset, insomnia, vivid dreams, akathisia, cholinergic rebound (sweating, salivation, cramps), anxiety. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Tofranil (imipramine)?
Slow hyperbolic taper recommended due to anticholinergic rebound. Compounded liquid useful for fine cuts at the low end. Reduce by smaller proportional steps as the dose gets lower. Cholinergic rebound (sweating, abdominal cramps, malaise) is common and often misread as relapse.
How long does Tofranil withdrawal last?
Tofranil withdrawal typically begins 1-3 days after dose reduction, peaks around 5-10 days, and resolves within 2-6 weeks for most symptoms. Sleep disturbance and emotional reactivity can persist 1-3 months
Can I stop Tofranil cold turkey?
Stopping Tofranil abruptly is not recommended. Its half-life is 11-25 hours (parent); active metabolite desipramine 12-24 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Tofranil stay in your system?
Tofranil (imipramine) has a half-life of 11-25 hours (parent); active metabolite desipramine 12-24 hours. As a rule of thumb, a drug is mostly cleared after about five half-lives. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Tofranil (imipramine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.